Biomimetic Nanoparticles Carrying EP300 Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible lung disease with limited treatment options. SGC-CBP30, a CBP/EP300 inhibitor, shows anti-fibrotic activity but suffers from poor bioavailability and tissue specificity. Here, we developed platelet membrane-coated nanoparticles (PNP) for targeted pulm...